Literature DB >> 19165632

Correspondence between neurological deficit, cerebral infarct size, and Rho-kinase activity in a rat cerebral thrombosis model.

Koh Kawasaki1, Kazuo Yano, Kunie Sasaki, Shunsuke Tawara, Ichiro Ikegaki, Shin-Ichi Satoh, Yuji Ohtsuka, Yuki Yoshino, Hiroshi Kuriyama, Toshio Asano, Minoru Seto.   

Abstract

Whether Rho-kinase activity is really associated with the pathogenesis of cerebral infarction remains unclear. To consider this question, we investigated correspondences between severity of neurological deficit, infarct size, amount of various marker proteins, and Rho-kinase activity in a rat cerebral infarction model. Sodium laurate was injected into the left internal carotid artery, inducing cerebral infarction in the ipsilateral hemisphere in rats. We prepared rats with various severities of neurological deficit (mild to severe) 3 days after injection of laurate, then measured infarct size and amount of various marker proteins, phosphorylation of substrates of Rho-kinase, myosin-binding subunit (MBS), myosin light chain (MLC), ezrin/radixin/moesin (ERM), and adducin using Western blot methods. First, infarct size increased corresponding to the severity of neurological deficit. Second, amounts of activating transcription factor 3, nestin, CD68, proliferating cell nuclear antigen, and heat shock protein 70 were increased, whereas neurofilament and myelin-associated glycoprotein were decreased corresponding to the severity of neurological deficit and infarct size. Finally, Rho-kinase activity (phospho-MBS/MBS, phospho-MLC/MLC, phospho-ERM/ERM, and phospho-adducin/adducin) was increased corresponding to the severity of neurological deficit and infarct size. Rho-kinase thus appears to play a crucial role in the pathogenesis of cerebral infarction.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19165632     DOI: 10.1007/s12031-009-9175-x

Source DB:  PubMed          Journal:  J Mol Neurosci        ISSN: 0895-8696            Impact factor:   3.444


  33 in total

Review 1.  Regulation and functions of Rho-associated kinase.

Authors:  M Amano; Y Fukata; K Kaibuchi
Journal:  Exp Cell Res       Date:  2000-11-25       Impact factor: 3.905

Review 2.  Rho kinase, a promising drug target for neurological disorders.

Authors:  Bernhard K Mueller; Helmut Mack; Nicole Teusch
Journal:  Nat Rev Drug Discov       Date:  2005-05       Impact factor: 84.694

3.  Rho family GTPases and neuronal growth cone remodelling: relationship between increased complexity induced by Cdc42Hs, Rac1, and acetylcholine and collapse induced by RhoA and lysophosphatidic acid.

Authors:  R Kozma; S Sarner; S Ahmed; L Lim
Journal:  Mol Cell Biol       Date:  1997-03       Impact factor: 4.272

4.  Rho-kinase inhibition acutely augments blood flow in focal cerebral ischemia via endothelial mechanisms.

Authors:  Hwa Kyoung Shin; Salvatore Salomone; E Michelle Potts; Sae-Won Lee; Eric Millican; Kensuke Noma; Paul L Huang; David A Boas; James K Liao; Michael A Moskowitz; Cenk Ayata
Journal:  J Cereb Blood Flow Metab       Date:  2006-10-11       Impact factor: 6.200

5.  Pharmacological profile of hydroxy fasudil as a selective rho kinase inhibitor on ischemic brain damage.

Authors:  S Satoh; T Utsunomiya; K Tsurui; T Kobayashi; I Ikegaki; Y Sasaki; T Asano
Journal:  Life Sci       Date:  2001-08-10       Impact factor: 5.037

6.  Differential expression of Musashi1 and nestin in the adult rat hippocampus after ischemia.

Authors:  Yoshiki Yagita; Kazuo Kitagawa; Tsutomu Sasaki; Takaki Miyata; Hideyuki Okano; Masatsugu Hori; Masayasu Matsumoto
Journal:  J Neurosci Res       Date:  2002-09-15       Impact factor: 4.164

7.  Biphasic expression of activating transcription factor-3 in neurons after cerebral infarction.

Authors:  Norihiro Ohba; Mitsuyo Maeda; Saya Nakagomi; Michinari Muraoka; Hiroshi Kiyama
Journal:  Brain Res Mol Brain Res       Date:  2003-07-23

8.  Rho-kinase activation in endothelial cells contributes to expansion of infarction after focal cerebral ischemia.

Authors:  Yoshiki Yagita; Kazuo Kitagawa; Tsutomu Sasaki; Yasukazu Terasaki; Kenichi Todo; Emi Omura-Matsuoka; Kozo Kaibuchi; Masatsugu Hori
Journal:  J Neurosci Res       Date:  2007-08-15       Impact factor: 4.164

9.  Wide therapeutic time window for Rho-kinase inhibition therapy in ischemic brain damage in a rat cerebral thrombosis model.

Authors:  Shin-ichi Satoh; Yoshinori Toshima; Asako Hitomi; Ichiro Ikegaki; Minoru Seto; Toshio Asano
Journal:  Brain Res       Date:  2007-12-04       Impact factor: 3.252

10.  Phosphorylation of myosin-binding subunit (MBS) of myosin phosphatase by Rho-kinase in vivo.

Authors:  Y Kawano; Y Fukata; N Oshiro; M Amano; T Nakamura; M Ito; F Matsumura; M Inagaki; K Kaibuchi
Journal:  J Cell Biol       Date:  1999-11-29       Impact factor: 10.539

View more
  3 in total

1.  Inhibition of myosin light chain kinase reduces NADPH oxidase-mediated oxidative injury in rat brain following cerebral ischemia/reperfusion.

Authors:  Hong-Feng Zhang; Ting-Bo Li; Bin Liu; Zheng Lou; Jie-Jie Zhang; Jing-Jie Peng; Xiao-Jie Zhang; Qi-Lin Ma; Jun Peng; Xiu-Ju Luo
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  2015-04-29       Impact factor: 3.000

2.  Mild hypothermia modulates the expression of nestin and caspase-3 in the sub-granular zone and improves neurological outcomes in rats with ischemic stroke.

Authors:  Dan Yu; Xueying Wang; Feng Zhou; Liang Wang; Guoshuai Yang; Wei Zhong; Ying Li; Zhiping Zhou; Aiyue Wang; Yanhui Zhou
Journal:  Oncotarget       Date:  2017-11-24

3.  DL-3-n-butylphthalide protects H9c2 cardiomyoblasts from ischemia/reperfusion injury by regulating HSP70 expression via PI3K/AKT pathway activation.

Authors:  Yunchen Yu; Yuying Zhu; Xiaotong Sun; Yongxing Li; Mingling Wang; Bin Dong; Xiaodong Sun; Wenming Hou
Journal:  Exp Ther Med       Date:  2021-07-15       Impact factor: 2.447

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.